Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension

Blood Pressure

Volumn 11, Issue 3, 2002, Pages 166-172

  Prichard, Brian N C ^a   Jäger, Bodo A ^a   Luszick, Joachim H ^a   Küster, Leslie J ^a   Verboom, Caes N ^a   Hughes, Peter R ^a   Sauermann, Wilhelm ^a   Küppers, Hartmut E ^a  

^a Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

24 h blood pressure monitoring; Controlled clinical trial; Enalapril; Essential hypertension; Moxonidine

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IMIDAZOLINE I1 RECEPTOR; MOXONIDINE; PLACEBO;

ADULT; AGED; ARTICLE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO; XEROSTOMIA;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; PLACEBOS; POSTURE; THERAPEUTIC EQUIVALENCY;

EID: 0036305976     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370502760050403     Document Type: Article

References (27)

1. 1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: Implications for the treatment of the elderly
2. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect
3. A double-blind comparison of moxonidine and atenolol in the management of patients with mild-to-moderate hypertension
4. Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril
5. The treatment of hypertensive patients with a calcium antagonist or moxonidine: A comparison
6. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension
7. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo
8. Crossover comparison of moxonidine and clonidine in mild-to-moderate hypertension
9. Safety and tolerability of moxonidine in the treatment of hypertension
10. Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy
11. Behavior of ambulatory blood pressure surrounding episodes of headache in mildly hypertensive patients
12. Placebo-associated blood pressure response and adverse effects in the treatment of hypertension: Observations from a Department of Veterans Affairs Cooperative Study
13. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension
14. Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target?
15. Contribution of sympathetic nervous system overactivity to cardiovascular and metabolic disease
16. Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB)
17. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat
18. Selective imidazoline receptor agonists for metabolic syndrome
19. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus
20. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
21. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease
22. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Results of the Hypertension Optimal Treatment (HOT) randomised trial
23. Requirements for antihypertensive therapy in diabetic patients: Metabolic aspects
24. Hypertension and diabetes: New therapeutic options
25. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
26. Use of moxonidine as initial therapy and in combination in the treatment of essential hypertension - Results of the TOPIC (Treatment of Physiotens In Combination) study
27. The use of moxonidine in the treatment of hypertension